Kezar Life Sciences, Inc. (KZR)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kezar Life Sciences, Inc. (KZR) trades at $6.90 with AI Score 44/100 (Weak). Kezar Life Sciences is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for immune-mediated diseases and cancer. Market cap: $50.53M, Sector: Healthcare.
Last analyzed: Feb 9, 2026Kezar Life Sciences, Inc. (KZR) Healthcare & Pipeline Overview
Kezar Life Sciences pioneers innovative treatments for immune-mediated diseases and cancer, driven by its lead immunoproteasome inhibitor, KZR-616, currently in Phase 2 trials. With a focused pipeline and a market cap of $0.04 billion, Kezar offers a compelling, albeit high-risk, investment opportunity in the biotechnology sector.
Investment Thesis
Kezar Life Sciences presents a high-risk, high-reward investment opportunity centered on its innovative approach to treating immune-mediated diseases and cancer. The primary value driver is KZR-616, currently in Phase 2 trials. Positive clinical data from these trials could serve as a significant catalyst, driving substantial stock appreciation. The company's market cap of $0.04 billion suggests significant upside potential if KZR-616 proves effective and gains regulatory approval. Further, the advancement of preclinical assets like KZR-261 and KZR-TBD offers additional long-term growth opportunities. However, investors must acknowledge the inherent risks associated with clinical-stage biotechnology companies, including clinical trial failures, regulatory hurdles, and the need for additional capital.
Based on FMP financials and quantitative analysis
Key Highlights
- KZR-616 is in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis, targeting significant unmet needs in immune-mediated diseases.
- KZR-261, a novel first-in-class protein secretion inhibitor, is in preclinical development, offering potential for future pipeline expansion.
- The company has a market capitalization of $0.04 billion, indicating potential for significant growth if clinical trials are successful.
- Kezar's P/E ratio is -0.73, reflecting its current lack of profitability as a clinical-stage company.
- The company's beta of 0.55 suggests lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Novel therapeutic approach with KZR-616.
- Pipeline of preclinical assets with potential for future growth.
- Experienced management team.
- Focus on unmet medical needs in immune-mediated diseases and cancer.
Weaknesses
- Clinical-stage company with no currently approved products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
- High risk of clinical trial failure.
Catalysts
- Upcoming: Release of Phase 2 clinical trial data for KZR-616 in lupus nephritis.
- Upcoming: Initiation of clinical trials for KZR-261.
- Ongoing: Continued enrollment in ongoing Phase 2 clinical trials.
- Ongoing: Potential for strategic partnerships or collaborations.
Risks
- Potential: Clinical trial failures for KZR-616 or other pipeline assets.
- Potential: Regulatory delays or rejection of marketing applications.
- Ongoing: Competition from other companies developing therapies for immune-mediated diseases and cancer.
- Ongoing: Need for additional capital to fund clinical development and operations.
- Potential: Intellectual property challenges.
Growth Opportunities
- Expansion of KZR-616 into additional indications: Kezar has the opportunity to expand the use of KZR-616 beyond its current Phase 2 trials. Exploring its efficacy in other autoimmune diseases with similar inflammatory pathways could significantly increase its market potential. The market for autoimmune disease therapies is estimated to reach billions of dollars, providing a substantial growth avenue for Kezar.
- Advancement of KZR-261 into clinical trials: KZR-261, a novel protein secretion inhibitor, represents a promising preclinical asset. Successfully transitioning KZR-261 into clinical trials would validate its mechanism of action and open up new therapeutic possibilities. The market for protein secretion inhibitors in oncology and immunology is largely untapped, offering a first-mover advantage for Kezar.
- Strategic partnerships and collaborations: Kezar can leverage strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. Collaborations can provide access to funding, expertise, and global distribution networks, enhancing Kezar's ability to bring its therapies to market. This could involve licensing agreements or joint development programs.
- Expansion of oncology pipeline: Kezar's KZR-TBD program targets both oncology and immunology indications. Focusing on specific cancer types with unmet needs and developing targeted therapies could create significant value. The oncology market is one of the largest and fastest-growing segments of the pharmaceutical industry, offering substantial growth potential.
- Acquisition or in-licensing of complementary assets: Kezar can expand its pipeline by acquiring or in-licensing complementary assets that align with its therapeutic focus. This could involve acquiring rights to promising preclinical or clinical-stage compounds that address similar disease pathways or patient populations. This strategy can diversify Kezar's portfolio and reduce its reliance on a single lead product.
Opportunities
- Expansion of KZR-616 into additional indications.
- Advancement of preclinical assets into clinical trials.
- Strategic partnerships and collaborations.
- Acquisition or in-licensing of complementary assets.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Need for additional capital.
Competitive Advantages
- Proprietary small molecule therapeutics targeting novel mechanisms of action.
- Strong intellectual property protection for its drug candidates.
- Clinical trial data demonstrating efficacy and safety.
- Experienced management team with expertise in drug development and commercialization.
About KZR
Kezar Life Sciences, Inc., founded in 2015 and headquartered in South San Francisco, California, is a clinical-stage biotechnology company dedicated to the discovery and development of transformative small molecule therapeutics. The company addresses significant unmet medical needs in immune-mediated diseases and cancer. Kezar's primary focus is on modulating the immune system to treat a range of debilitating conditions. Their lead product candidate, KZR-616, a selective immunoproteasome inhibitor, represents a novel approach to treating autoimmune diseases by selectively targeting the immunoproteasome, a key regulator of inflammation. KZR-616 is currently in Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis, and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Beyond KZR-616, Kezar is advancing a pipeline of preclinical assets, including KZR-261, a first-in-class protein secretion inhibitor, and KZR-TBD, targeting both oncology and immunology indications. Kezar's strategy involves identifying and developing innovative small molecule therapies with the potential to significantly improve patient outcomes in areas with limited treatment options.
What They Do
- Develop novel small molecule therapeutics.
- Focus on treatments for immune-mediated diseases.
- Target unmet needs in cancer treatment.
- Advance KZR-616, a selective immunoproteasome inhibitor, through clinical trials.
- Develop KZR-261, a first-in-class protein secretion inhibitor.
- Conduct preclinical research for new therapeutic candidates.
Business Model
- Discover and develop novel drug candidates.
- Conduct preclinical and clinical trials to evaluate safety and efficacy.
- Seek regulatory approval from the FDA.
- Potentially commercialize approved products directly or through partnerships.
Industry Context
Kezar Life Sciences operates within the competitive biotechnology industry, which is characterized by rapid innovation, high R&D costs, and stringent regulatory requirements. The market for immune-mediated disease therapies is substantial and growing, driven by an aging population and increased prevalence of autoimmune disorders. Key trends include the development of targeted therapies, such as immunoproteasome inhibitors, and the increasing use of biomarkers to personalize treatment. Kezar competes with larger pharmaceutical companies and other biotechnology firms focused on similar therapeutic areas. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies.
Key Customers
- Patients suffering from immune-mediated diseases such as lupus nephritis, dermatomyositis, and polymyositis.
- Patients with cancer who may benefit from novel therapies.
- Healthcare providers who prescribe and administer Kezar's therapies.
- Potential pharmaceutical partners interested in licensing or acquiring Kezar's assets.
Financials
Chart & Info
Kezar Life Sciences, Inc. (KZR) stock price: $6.90 (+0.00, +0.00%)
Latest News
-
12 Health Care Stocks Moving In Monday's Intraday Session
benzinga · Mar 30, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KZR.
Price Targets
Wall Street price target analysis for KZR.
MoonshotScore
What does this score mean?
The MoonshotScore rates KZR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest Kezar Life Sciences, Inc. Analysis
What Investors Ask About Kezar Life Sciences, Inc. (KZR)
What does Kezar Life Sciences, Inc. do?
Kezar Life Sciences is a clinical-stage biotechnology company focused on discovering and developing novel small molecule therapeutics to address unmet needs in immune-mediated diseases and cancer. Their lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently in Phase 2 clinical trials for various autoimmune disorders. The company also has preclinical programs, including KZR-261, a protein secretion inhibitor, targeting oncology and immunology. Kezar's business model revolves around advancing these drug candidates through clinical development and ultimately seeking regulatory approval and commercialization, either independently or through partnerships.
Is KZR stock worth researching?
KZR stock represents a speculative investment opportunity with significant potential upside and substantial risk. The company's value is primarily tied to the success of KZR-616 in its ongoing Phase 2 clinical trials. Positive data could drive significant stock appreciation, while negative results could have a detrimental impact. With a market cap of $0.04 billion, Kezar offers potential for high returns, but investors should carefully consider the inherent risks associated with clinical-stage biotechnology companies, including the possibility of clinical trial failures and the need for additional financing. A balanced approach is crucial.
What are the main risks for KZR?
The primary risks for Kezar Life Sciences revolve around the clinical development of its drug candidates. Clinical trial failures represent a significant threat, as negative results could halt the development of KZR-616 or other pipeline assets. Regulatory hurdles and potential delays in obtaining marketing approvals also pose risks. Furthermore, Kezar faces competition from larger pharmaceutical companies with greater resources. The company's need for additional capital to fund its operations and clinical trials could lead to dilution of existing shareholders. These factors contribute to the high-risk profile of KZR stock.
What are the key factors to evaluate for KZR?
Kezar Life Sciences, Inc. (KZR) currently holds an AI score of 44/100, indicating low score. Key strength: Novel therapeutic approach with KZR-616.. Primary risk to monitor: Potential: Clinical trial failures for KZR-616 or other pipeline assets.. This is not financial advice.
How frequently does KZR data refresh on this page?
KZR prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KZR's recent stock price performance?
Recent price movement in Kezar Life Sciences, Inc. (KZR) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel therapeutic approach with KZR-616.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider KZR overvalued or undervalued right now?
Determining whether Kezar Life Sciences, Inc. (KZR) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying KZR?
Before investing in Kezar Life Sciences, Inc. (KZR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on information available as of 2026-02-09 and may be subject to change.
- Investment decisions should be based on thorough due diligence and consultation with a financial advisor.